贝伐珠单抗联合紫杉类药物一线治疗局部复发或转移性乳腺癌患者的安全性及疗效

Safety and Efficacy of Bevacizumab Combined with Taxanes for First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer

[目的]研究贝伐珠单抗联合紫杉类药物一线治疗Her-2阴性的局部复发或转移性乳腺癌患者的安全性和疗效。[方法]32例Her-2阴性的复发或转移性乳腺癌患者,一线接受贝伐珠单抗联合紫杉类方案的化疗,直至疾病进展或不良反应不能耐受或患者要求出组。研究者选择化疗方案:贝伐珠单抗15mg/kg静滴d1,多西他赛75mg/m2,静滴d1,21d为一个周期;或贝伐珠单抗10mg/kg静滴d1,15,紫杉醇80mg/m2,静滴d1,8,15,28d为一个周期。每3个周期评价疗效。[结果]32例可评价疗效和副作用,PR16例,SD15例,PD1例,总有效率50%,中位TTP为7.25个月。3级以上不良反应为阴道出血、粒细胞下降以及腹泻。[结论]贝伐珠单抗联合紫杉类药物治疗晚期乳腺癌不良反应可以耐受,具有一定疗效。

[Purpose ] To investigate safety and efficacy of bevacizumab combined with taxane-based therapy as a first-line regimen for patients with Her2-negative locally recurrent（LR）/metastatic breast cancer（mBC）.[Methods] Thirty-two cases with Her2-negative LR/mBC received bevacizumab combined with taxane-based therapy until disease progression,unacceptable toxicity,or consent withdrawal. Chemotherapy regimens ：bevacizumab 15mg/kg i.v. on dl and docetaxel 75mg/m2 on d1 every 21 days;or bevacizumab 10mg/kg i.v. d1,d15 paclitaxel 80mg/m2 dl,s,15,every 28 days. Radiologic tumor assessments were performed after every 3 cycles of therapy. [Results] Of 32 cases, 16 cases achieved PR;15,stable disease and 1 ,progress disease. The overall response rate（ORR） was 50%.The median time to progression was 7.25 months. Grade 3 adverse events were vaginal bleeding, neutropenia and diarrhoea. [Conclusions] Combination of bevacizumab and taxane-based therapy is an effective regimen for patients with Her-2 negative LR/mBC and the toxicity is acceptable.